Belimumab

Drug Profile

Belimumab

Alternative Names: Anti-BLyS monoclonal antibody; Benlysta; BmAb; GSK1550188; HGS-1006; LymphoStat-B

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge Antibody Technology; Human Genome Sciences
  • Developer Assistance Publique Hopitaux de Paris; Cancer Trials Australia; GlaxoSmithKline; Hospital for Special Surgery; Human Genome Sciences; North Shore-Long Island Jewish Health System; University of Pennsylvania
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Systemic lupus erythematosus
  • Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis; Lupus nephritis
  • Phase II/III Myositis
  • Phase II Membranous glomerulonephritis; Myasthenia gravis; Renal transplant rejection; Sjogren's syndrome; Systemic scleroderma
  • No development reported Waldenstrom's macroglobulinaemia
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 21 Jul 2017 Registered for Systemic lupus erythematosus (Treatment-experienced) in USA (SC)
  • 21 Jul 2017 GlaxoSmithKline announces intention to file regulatory submissions for subcutaneous belimumab in countries other than USA, European Union and Japan for Systemic lupus erythematosus in 2017
  • 16 Jun 2017 Final efficacy data from a phase II extension trial in Systemic lupus erythematosus presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top